ZNTL beat EPS expectations by 15.34%
Apr 02, 2026, 10:35 PM
0.00%
What does ZNTL do
Zentalis Pharmaceuticals, a San Diego-based clinical-stage biopharmaceutical company, develops novel small molecule therapeutics for cancer, including WEE1 inhibitor azenosertib and BCL-2 inhibitor ZN-d5. The company went public on April 3, 2020, and employs 168 people.
Zentalis Pharmaceuticals (ZNTL) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Zentalis Pharmaceuticals's actual EPS was -$0.50, beating the estimate of -$0.59 per share, resulting in a 15.34% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.